A Study to Evaluate GSK1325760A - a Long-Term Extension Study

Exclusion Criteria

• •Subjects who have been withdrawn from the Phase II/III study.
• •Female subjects who wish to become pregnant.
• •Treatment with other PAH medication is needed.
• •A worsening of 2 or more levels of the WHO Functional Classification (see Appendix 2.1) comparing with the baseline of Phase II/III study (Study No.AMB107816).
• •Worsening of right ventricular failure (e.g. as indicated by increased jugular venous pressure, new/worsened hepatomegaly, ascites, or peripheral edema) during Phase II/III study (Study No.AMB107816).
• •Rapidly progressing cardiac, hepatic or renal failure during Phase II/III study (Study No.AMB107816).
• •Participation to the long-term extension study is considered as inappropriate in the judgment of the investigator or subinvestigator.